The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Responses rates and outcome to neoadjuvant chemotherapy in triple-negative breast cancers (TNBC).
S. P. Neciosup
No relevant relationships to disclose
L. Ventura
No relevant relationships to disclose
H. Gomez
No relevant relationships to disclose
J. A. Pinto
No relevant relationships to disclose
M. J. Marcelo
No relevant relationships to disclose
T. Vidaurre
No relevant relationships to disclose
C. Vallejos Sologuren
No relevant relationships to disclose